Results 161 to 170 of about 99,136 (277)

Incidence and Outcome of Infants With Cancer in Canada: A Report From Cancer in Young People in Canada Database

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Purpose Infants with cancer are rare and face unique challenges. Our study aims to describe the incidence of infantile cancers in Canada and to compare treatment‐related mortality (TRM) and their outcomes with those of older children. Methods We conducted a retrospective cohort study using the Cancer in Young People in Canada database ...
Samuel Sassine, Hallie Coltin, Maria Kondyli, Monia Marzouki, Nicolas Prud'homme, Nida Usmani, Sylvia Cheng, Lesleigh Abbott, Tony Truong, Sapna Oberoi, Ketan Kulkarni, Josée Brossard, Lynette Bowes, Paul Gibson, Donna L. Johnston, Sarah McKillop, Roona Sinha, Lillian Sung, Catherine Vezina, Laura Wheaton, Alexandra P. Zorzi, Marie‐Claude Pelland‐Marcotte, Thai Hoa Tran   +22 more
wiley   +1 more source

Advances in the study of TIM3 in myelodysplastic syndrome. [PDF]

Front Immunol
Guo X, Yu S, Tao J, Wang Y, Shao Z, Fu R, Li L.   +6 more
europepmc   +1 more source

New Insights Into Factors Shaping CMV‐Specific T‐Cell Polyfunctionality After Hematopoietic Cell Transplantation

American Journal of Hematology, Volume 101, Issue 2, Page 255-268, February 2026.
ABSTRACT Polyfunctional cytomegalovirus (CMV)‐specific T cells are critical for antiviral immunity in allogeneic hematopoietic cell transplantation (HCT) recipients. However, gaps remain in managing refractory CMV and optimizing virus‐specific cellular therapy (VST).
Alicja Sadowska‐Klasa, Fang Yun Lim, Hu Xie, Danniel Zamora, Terry Stevens‐Ayers, Wendy M. Leisenring, Bradley C. Edmison, Stephen C. De Rosa, Marco Mielcarek, Michael Boeckh   +9 more
wiley   +1 more source

Treatment of Relapsed/Refractory t(11;14) Multiple Myeloma and High-Risk Myelodysplastic Syndrome With Venetoclax. [PDF]

Case Rep Hematol
Taylor AO, Clune S, Liu J, Gasparetto C, LeBlanc TW.   +4 more
europepmc   +1 more source

Why We Do Not Recommend That People With High‐Risk Smoldering Myeloma Receive Treatment

American Journal of Hematology, Volume 101, Issue 3, Page 409-412, March 2026.
Ghulam Rehman Mohyuddin, Mackenzie Lemieux, Rajshekhar Chakraborty, Morie Gertz   +3 more
wiley   +1 more source

Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT

American Journal of Hematology, Volume 101, Issue 2, Page 281-290, February 2026.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for secondary acute myeloid leukemia (sAML). This study compared haploidentical donor (Haplo), matched sibling donor (MSD), and matched unrelated donor (MUD) HSCT in patients with sAML in first complete remission (CR1).
Arnon Nagler, Sarah Kayser, Allain Thibeault Ferhat, Nicolaus Kröger, Matthias Eder, Gérard Socié, Didier Blaise, Thomas Schroeder, Hélène Labussière‐Wallet, Johan Maertens, Alessandro Busca, Edouard Forcade, Tobias Gedde‐Dahl, Alessandro Rambaldi, Claude Eric Bulabois, Gesine Bug, Ali Bazarbachi, Eolia Brissot, Bipin Savani, Mohamad Mohty, Fabio Ciceri   +20 more
wiley   +1 more source

FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome. [PDF]

J Clin Invest
Niederkorn M, Bezavada L, Cotton A, Palmer LE, Konada L, Hall T, Pagala VR, Zhai J, Yuan ZF, Fu Y, Steele JA, Narina S, Schild A, Wu C, Aminov S, Schieber M, McGovern E, Taylor AB, Gurbuxani S, Xu P, Ji P, Janke LJ, High AA, Kang G, Pruett-Miller SM, Weiss M, Verma A, Rampal RK, Crispino JD.   +28 more
europepmc   +1 more source

Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia. [PDF]

Cancers (Basel)
Hunter CJ, Im AP, Shallis RM.
europepmc   +1 more source

Prediction of neutrophil nadir and recovery following paediatric haematopoietic cell transplantation with busulfan conditioning

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 568-578, February 2026.
Aims In haematopoietic cell transplantation (HCT), neutropenia resulting from myelosuppression is an expected endpoint following busulfan‐based conditioning. However, if prolonged, neutropenia can lead to complications like serious infection and death.
Beth Apsel Winger, Joseph W. Polli, Janel Long‐Boyle, Andrew Weber, Jordan Brooks, Jaimit Parikh, Valeriu Damian   +6 more
wiley   +1 more source

Atypical orbital mass as the precursor for myelodysplastic syndrome recurrence: a case report. [PDF]

Am J Ophthalmol Case Rep
Demas N, Hernandez J, Timoney P.
europepmc   +1 more source